Developer docs
API playgroundTry for free, no card

Search company profiles

PredxBio

Full company profile

uuid0002b4x

Namestring
PredxBio
Legal namestring
PredxBio, Inc.
Websiteurl
predxbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

PredxBio is a Pittsburgh-based computational pathology company that develops AI-driven spatial biology software for biopharmaceutical drug development. The company's core product, the SpaceIQ decision-intelligence platform, applies explainable AI to whole-slide tissue images and multi-omic data (H&E, IHC, mIF, IMC, spatial proteomics, and spatial transcriptomics) to characterize tissue organization, cellular microenvironments, and cell–cell interactions across multiple biological scales. The platform is organized into three application layers — Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support — and is positioned to support target and biomarker strategy, patient stratification, trial optimization, and go/no-go decisions in oncology drug programs. The company also retains the legacy HistoMapr-Breast™ computational pathology product for breast cancer diagnosis and prognosis.

PredxBio operates an enterprise-direct, sales-led go-to-market motion targeting two horizontal segments: biopharmaceutical companies (primary) and academic research institutions (secondary). The commercial model begins with collaborative, fee-based research engagements, then transitions customers to subscription/recurring SpaceIQ platform licensing — available as cloud-based access or on-premise deployment — once programs mature. Deployment is supported by a partnership ecosystem spanning imaging (Hamamatsu Photonics), virtual staining (PictorLabs), multi-omic CRO services (Sirona Dx, iCura Diagnostics), and digital pathology platforms (Inspirata, CellNetix). The company markets through scientific conferences (AACR, SITC), content marketing, LinkedIn, YouTube, and its own Spatial Intelligence Summit.

The company is privately held, incorporated in Delaware, with 11–50 employees and headquarters in Pittsburgh, PA. It was founded in 2015 (originally as SpIntellx, rebranded in April 2023) and has raised approximately $1.1M in disclosed equity funding across a 2020 round and a 2023 SEC Form D exempt offering of up to $4M. In December 2025, co-founder S. Chakra Chennubhotla, PhD was appointed CEO, succeeding B. Dusty Majumdar, PhD.

Short descriptiontext

PredxBio builds the SpaceIQ AI-driven spatial biology platform, which applies explainable AI to tissue and multi-omic data to deliver decision-grade biomarkers, patient stratification, and trial optimization for biopharmaceutical drug development and academic oncology research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology analytics, computational pathology software, explainable AI platform, tissue intelligence solutions, biomarker discovery tools
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Pathology Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software Platform Licensing
TypeSubscription Recurring
Description

PredxBio transitions from collaborative research engagements to secure, scalable, and modular software access. As insights mature from exploration to program dependency, SpaceIQ transitions from collaboration to platform licensing. Deployment models include cloud-based access, on-premise deployment, and enterprise integration.

predxbio.com
2Collaborative Research Engagements
TypeProfessional Services
Description

Partners with biopharma teams through collaborative, knowledge-driven research engagements. Revenue generated through research collaboration fees before transitioning to ongoing platform licensing.

predxbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1SpaceIQ™
Description

Decision-intelligence platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development.

predxbio.com
+1 more record
Core offering1 text field

PredxBio develops and licenses the SpaceIQ™ decision-intelligence platform, an AI-driven spatial biology software that combines unbiased spatial analytics with explainable AI to analyze whole slide image and multi-omic tissue data for drug discovery, biomarker development, and clinical trial optimization. The company also offers the HistoMapr-Breast™ computational pathology application for breast cancer diagnosis and provides collaborative research engagements that transition into platform licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Earlier go/no-go decisions in drug development
+2 more records
Product overview1 text field

PredxBio offers the SpaceIQ™ decision intelligence platform as its core product, complemented by specialized sub-products including Discovery & Mechanism Intelligence, Translational & Clinical Readiness, Trial & Program-Scale Decision Support, and the Multi-Omic Co-Analysis feature. The platform is augmented by HistoMapr-Breast™ for computational pathology. Services include collaborative research engagements transitioning to platform licensing. SpaceIQ integrates unbiased spatial analytics with explainable AI to transform complex tissue and multi-omic spatial data into explainable, decision-ready insights across drug discovery and clinical development.

Product and service4 records
1SpaceIQ™ Platform
CategoryDecision Intelligence Software
Description

An end-to-end decision-intelligence software platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development. Delivered via cloud-based access or on-premise deployment to biopharmaceutical companies and research institutions.

2HistoMapr-Breast™
CategoryComputational Pathology Software
Description

Computational pathology software that uses explainable AI (xAI) and spatial analytics to help healthcare providers diagnose, prognosticate, and treat breast cancer more efficiently and accurately.

3Collaborative Research Engagements
CategoryResearch Services
Description

Knowledge-driven research service engagements with biopharma teams, providing a pathway from exploratory research collaboration to SpaceIQ platform licensing as insights mature into program dependencies.

4SaaS for Precision Pathology
CategorySoftware as a Service
Description

Software-as-a-service offering that delivers PredxBio's unbiased spatial analytics and explainable AI for accelerated drug discovery, biomarker identification, clinical trials optimization, and precision patient stratification.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Strategic collaboration uniting Hamamatsu's advanced MoxiePlex™ multiplex immunofluorescence imaging system with PredxBio's SpaceIQ™ spatial analytics platform to deliver an integrated workflow tailored to immuno-oncology research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-23
Description

Collaboration to unlock actionable biology from immunotherapy studies and develop a highly selective, spatial-biomarker-based companion diagnostic for predicting immunotherapy response. Also introduced predictive test framework for translating high-plex spatial data into robust, clinically deployable predictive biomarkers.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-04-09
Description

Strategic partnership to revolutionize cancer research, diagnosis, and treatment by combining PredxBio's spatial analytics with PictorLabs' AI-powered virtual staining technology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-04-02
Description

Strategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics for drug discovery and development.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-08-18
Description

Partnership to expand access to advanced spatial analytics and explainable AI products for pathology and oncology research, leveraging iCura's contract research organization capabilities.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2020-07-20
Description

Collaboration to validate HistoMapr-Breast™ Platform featuring advanced spatial analytics to provide intelligent guides for pathology laboratories diagnosing and treating breast cancer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics offers the Xenium spatial transcriptomics platform and配套 Visium HD workflow, competing directly with PredxBio's SpaceIQ in spatial multi-omic analysis for biopharma and academic research customers. Both target tissue-level insights for drug discovery and translational research.

TypeDirect peer
Description

Akoya Biosciences provides the PhenoCycler (CODEX) spatial proteomics platform plus Phenoptics analysis software for immuno-oncology biomarker discovery. Direct overlap with PredxBio on spatial proteomics-driven tissue analysis for pharma translational programs.

TypeDirect peer
Description

NanoString, now part of Bruker Spatial Biology, offers the CosMx SMI spatial molecular imager and GeoMx digital spatial profiler, directly competing with SpaceIQ in high-plex spatial transcriptomics and proteomics for pharma and translational research customers.

TypeDirect peer
Description

Lunaphore develops the COMET multiplex staining and staining-and-imaging platform for spatial proteomics with comparable end-user applications in immuno-oncology biomarker discovery, overlapping with PredxBio's spatial biology value proposition.

TypeDirect peer
Description

PathAI applies AI to pathology images for biomarker discovery, diagnostic development, and pharma partnerships, directly overlapping with PredxBio's computational pathology and pharma-services positioning across translational and clinical applications.

TypeDirect peer
Description

Owkin is an AI-biopharma company building pathology AI models and federated learning infrastructure for drug discovery and companion diagnostics, comparable to PredxBio in target customer (pharma), use cases (biomarker/patient stratification), and AI-first computational pathology focus.

7Aignostics
TypeDirect peer
Description

Aignostics builds AI-powered computational pathology models derived from H&E and IHC for biopharma biomarker discovery and CDx development, competing with PredxBio's spatial pathology analytics for similar pharma translational workflows.

TypeDirect peer
Description

Visiopharm provides image analysis software for digital pathology with deep tissue phenotyping capabilities used by biopharma and academic labs, overlapping with PredxBio's computational pathology software approach for oncology and translational research.

TypeDirect peer
Description

Indica Labs offers HALO and HALO AI digital pathology software for tissue image analysis, including multiplex phenotyping and spatial biology workflows comparable to SpaceIQ's tissue analysis capabilities for pharma and academic users.

TypeBroad incumbent
Description

Roche's Digital Pathology business (including navify Digital Pathology and the Ventana companion diagnostic franchise) is a broad incumbent serving pharma CDx and pathology AI use cases that partially overlap with PredxBio's biomarker and tissue intelligence offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PredxBio

Computational Pathology Softwarepredxbio.com

PredxBio builds the SpaceIQ AI-driven spatial biology platform, which applies explainable AI to tissue and multi-omic data to deliver decision-grade biomarkers, patient stratification, and trial optimization for biopharmaceutical drug development and academic oncology research.

What PredxBio does

PredxBio is a Pittsburgh-based computational pathology company that develops AI-driven spatial biology software for biopharmaceutical drug development. The company's core product, the SpaceIQ decision-intelligence platform, applies explainable AI to whole-slide tissue images and multi-omic data (H&E, IHC, mIF, IMC, spatial proteomics, and spatial transcriptomics) to characterize tissue organization, cellular microenvironments, and cell–cell interactions across multiple biological scales. The platform is organized into three application layers — Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support — and is positioned to support target and biomarker strategy, patient stratification, trial optimization, and go/no-go decisions in oncology drug programs. The company also retains the legacy HistoMapr-Breast™ computational pathology product for breast cancer diagnosis and prognosis.

PredxBio operates an enterprise-direct, sales-led go-to-market motion targeting two horizontal segments: biopharmaceutical companies (primary) and academic research institutions (secondary). The commercial model begins with collaborative, fee-based research engagements, then transitions customers to subscription/recurring SpaceIQ platform licensing — available as cloud-based access or on-premise deployment — once programs mature. Deployment is supported by a partnership ecosystem spanning imaging (Hamamatsu Photonics), virtual staining (PictorLabs), multi-omic CRO services (Sirona Dx, iCura Diagnostics), and digital pathology platforms (Inspirata, CellNetix). The company markets through scientific conferences (AACR, SITC), content marketing, LinkedIn, YouTube, and its own Spatial Intelligence Summit.

The company is privately held, incorporated in Delaware, with 11–50 employees and headquarters in Pittsburgh, PA. It was founded in 2015 (originally as SpIntellx, rebranded in April 2023) and has raised approximately $1.1M in disclosed equity funding across a 2020 round and a 2023 SEC Form D exempt offering of up to $4M. In December 2025, co-founder S. Chakra Chennubhotla, PhD was appointed CEO, succeeding B. Dusty Majumdar, PhD.

PredxBio firmographics

Firmographics
Name
PredxBio
Legal name
PredxBio, Inc.
Website
https://predxbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
PredxBio builds the SpaceIQ AI-driven spatial biology platform, which applies explainable AI to tissue and multi-omic data to deliver decision-grade biomarkers, patient stratification, and trial optimization for biopharmaceutical drug development and academic oncology research.
Ownership category
akta.pro rank

PredxBio industry classification

Industry
Product category
Computational Pathology Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Spatial biology analytics
  • Computational pathology software
  • Explainable AI platform
  • Tissue intelligence solutions
  • Biomarker discovery tools

Where PredxBio is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PredxBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Platform Licensing: PredxBio transitions from collaborative research engagements to secure, scalable, and modular software access. As insights mature from exploration to program dependency, SpaceIQ transitions from collaboration to platform licensing. Deployment models include cloud-based access, on-premise deployment, and enterprise integration.
  2. Collaborative Research Engagements: Partners with biopharma teams through collaborative, knowledge-driven research engagements. Revenue generated through research collaboration fees before transitioning to ongoing platform licensing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

PredxBio product offering

Product offering

Core offering

PredxBio develops and licenses the SpaceIQ™ decision-intelligence platform, an AI-driven spatial biology software that combines unbiased spatial analytics with explainable AI to analyze whole slide image and multi-omic tissue data for drug discovery, biomarker development, and clinical trial optimization. The company also offers the HistoMapr-Breast™ computational pathology application for breast cancer diagnosis and provides collaborative research engagements that transition into platform licensing.

Product overview

PredxBio offers the SpaceIQ™ decision intelligence platform as its core product, complemented by specialized sub-products including Discovery & Mechanism Intelligence, Translational & Clinical Readiness, Trial & Program-Scale Decision Support, and the Multi-Omic Co-Analysis feature. The platform is augmented by HistoMapr-Breast™ for computational pathology. Services include collaborative research engagements transitioning to platform licensing. SpaceIQ integrates unbiased spatial analytics with explainable AI to transform complex tissue and multi-omic spatial data into explainable, decision-ready insights across drug discovery and clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • SpaceIQ™: Decision-intelligence platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development.
  • HistoMapr-Breast™

Products and services

  • SpaceIQ™ Platform An end-to-end decision-intelligence software platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development. Delivered via cloud-based access or on-premise deployment to biopharmaceutical companies and research institutions.
  • HistoMapr-Breast™ Computational pathology software that uses explainable AI (xAI) and spatial analytics to help healthcare providers diagnose, prognosticate, and treat breast cancer more efficiently and accurately.
  • Collaborative Research Engagements Knowledge-driven research service engagements with biopharma teams, providing a pathway from exploratory research collaboration to SpaceIQ platform licensing as insights mature into program dependencies.
  • SaaS for Precision Pathology Software-as-a-service offering that delivers PredxBio's unbiased spatial analytics and explainable AI for accelerated drug discovery, biomarker identification, clinical trials optimization, and precision patient stratification.

Quantifiable outcome

  • Earlier go/no-go decisions in drug development
  • +2 more outcomes

Companies that use PredxBio

Customer profile

Segments2 records

Ideal customer profiles2 records

PredxBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

PredxBio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and minor.

  • Hamamatsu PhotonicscoreStrategic or Co-development Partner · 28 April 2025Strategic collaboration uniting Hamamatsu's advanced MoxiePlex™ multiplex immunofluorescence imaging system with PredxBio's SpaceIQ™ spatial analytics platform to deliver an integrated workflow tailored to immuno-oncology research.
  • University of Queensland (Dr. Arutha Kulasinghe, Queensland Spatial Biology Centre)coreStrategic or Co-development Partner · 23 April 2025Collaboration to unlock actionable biology from immunotherapy studies and develop a highly selective, spatial-biomarker-based companion diagnostic for predicting immunotherapy response. Also introduced predictive test framework for translating high-plex spatial data into robust, clinically deployable predictive biomarkers.
  • PictorLabsmajorTechnology or Integration · 9 April 2024Strategic partnership to revolutionize cancer research, diagnosis, and treatment by combining PredxBio's spatial analytics with PictorLabs' AI-powered virtual staining technology.
  • Sirona DxmajorStrategic or Co-development Partner · 2 April 2024Strategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics for drug discovery and development.
  • iCura DiagnosticsminorChannel Partner/ Reseller/ Distributor · 18 August 2022Partnership to expand access to advanced spatial analytics and explainable AI products for pathology and oncology research, leveraging iCura's contract research organization capabilities.
  • CellNetix Pathology & LaboratoriesminorImplementation/ SI/ Consulting Partner · 20 July 2020Collaboration to validate HistoMapr-Breast™ Platform featuring advanced spatial analytics to provide intelligent guides for pathology laboratories diagnosing and treating breast cancer.

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

PredxBio competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics offers the Xenium spatial transcriptomics platform and配套 Visium HD workflow, competing directly with PredxBio's SpaceIQ in spatial multi-omic analysis for biopharma and academic research customers. Both target tissue-level insights for drug discovery and translational research.
  • Akoya Biosciences: Akoya Biosciences provides the PhenoCycler (CODEX) spatial proteomics platform plus Phenoptics analysis software for immuno-oncology biomarker discovery. Direct overlap with PredxBio on spatial proteomics-driven tissue analysis for pharma translational programs.
  • NanoString Technologies (Bruker Spatial Biology): NanoString, now part of Bruker Spatial Biology, offers the CosMx SMI spatial molecular imager and GeoMx digital spatial profiler, directly competing with SpaceIQ in high-plex spatial transcriptomics and proteomics for pharma and translational research customers.
  • Lunaphore: Lunaphore develops the COMET multiplex staining and staining-and-imaging platform for spatial proteomics with comparable end-user applications in immuno-oncology biomarker discovery, overlapping with PredxBio's spatial biology value proposition.
  • PathAI: PathAI applies AI to pathology images for biomarker discovery, diagnostic development, and pharma partnerships, directly overlapping with PredxBio's computational pathology and pharma-services positioning across translational and clinical applications.
  • Owkin: Owkin is an AI-biopharma company building pathology AI models and federated learning infrastructure for drug discovery and companion diagnostics, comparable to PredxBio in target customer (pharma), use cases (biomarker/patient stratification), and AI-first computational pathology focus.
  • Aignostics: Aignostics builds AI-powered computational pathology models derived from H&E and IHC for biopharma biomarker discovery and CDx development, competing with PredxBio's spatial pathology analytics for similar pharma translational workflows.
  • Visiopharm: Visiopharm provides image analysis software for digital pathology with deep tissue phenotyping capabilities used by biopharma and academic labs, overlapping with PredxBio's computational pathology software approach for oncology and translational research.
  • Indica Labs: Indica Labs offers HALO and HALO AI digital pathology software for tissue image analysis, including multiplex phenotyping and spatial biology workflows comparable to SpaceIQ's tissue analysis capabilities for pharma and academic users.

Broad incumbents

  • Roche (Digital Pathology / navify): Roche's Digital Pathology business (including navify Digital Pathology and the Ventana companion diagnostic franchise) is a broad incumbent serving pharma CDx and pathology AI use cases that partially overlap with PredxBio's biomarker and tissue intelligence offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

PredxBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PredxBio leadership team

Management profile

Number of profiles

Profiles14 records

PredxBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PredxBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PredxBio

What does PredxBio do?

PredxBio develops and licenses the SpaceIQ™ decision-intelligence platform, an AI-driven spatial biology software that combines unbiased spatial analytics with explainable AI to analyze whole slide image and multi-omic tissue data for drug discovery, biomarker development, and clinical trial optimization. The company also offers the HistoMapr-Breast™ computational pathology application for breast cancer diagnosis and provides collaborative research engagements that transition into platform licensing.

Is PredxBio a public or private company?

PredxBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was PredxBio founded?

PredxBio was founded in 2015. It employs 11 to 50 people.

Where is PredxBio based?

PredxBio is headquartered in Pittsburgh, United States, in the North America region.

How does PredxBio make money?

Two revenue lines are on record. Software Platform Licensing is the primary driver. The others are collaborative Research Engagements.

Who are PredxBio's main competitors?

Direct peers on record are 10x Genomics, Akoya Biosciences, NanoString Technologies (Bruker Spatial Biology), Lunaphore, PathAI, Owkin, Aignostics, Visiopharm and Indica Labs. Roche (Digital Pathology / navify) is listed as a broad incumbent.

Does PredxBio have an API?

No public API is recorded for PredxBio.

What industry is PredxBio in?

PredxBio's product category is Computational Pathology Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGANAC, Single-Cell & Spatial Omics Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebPredxBio Announces Leadership Update and Strengthened Focus on Spatial Multi-Omic BiomarkersPredxBio announced a leadership transition, appointing S. Chakra Chennubhotla as CEO to support its growth. The company develops tissue-based spatial biomarkers using AI for oncology drug development.PrwebPredxBio Unveils Multi-omic Spatial Biomarkers at SITC 2025 Driving Immunotherapy Precision and Target DiscoveryPredxBio announced its participation at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, where it will host a Scientific Symposium and present results across four collaborative studies. The company will showcase its SpaceIQ™ platform, demonstrating how AI-driven spatial and multi-omic analytics can predict immunotherapy response and accelerate precision oncology development. The event is scheduled for November 5-9, 2025 at the Gaylord National Resort & Convention Center in National Harbor, MD.PrwebPredxBio Unveils Revolutionary SpaceIQ™ Platform Ushering in a New Era of Spatial Multi-Omics at 2024 AACR Annual MeetingPredxBio unveiled its SpaceIQ platform at the 2024 AACR Annual Meeting in San Diego (April 7–11), introducing a spatial multi-omics analytics system for cancer research. The platform combines spatial proteomics and transcriptomics with Explainable AI, claiming predictive accuracy exceeding 90% across multiple cancer indications. The announcement also highlighted the company's growing ecosystem of partnerships in cancer research and therapy development.SecSEC FORM DPredxBio, Inc. filed a Form D with the SEC on August 17, 2023, announcing an exempt securities offering under Rule 506(b) with a total target amount of $4 million. As of the filing date, the company had sold approximately $601,321 worth of equity securities to 11 investors.